Semaglutide vs Tesamorelin

You are choosing between two endocrine systems that happen to share a shelf. Semaglutide is a GLP-1 receptor agonist — an incretin analogue carrying a fatty-acid chain that binds albumin and stretches its half-life towards a week, which is why the published protocols around it are weekly. Tesamorelin is a stabilised growth-hormone-releasing hormone analogue with a circulating half-life measured in minutes, and the human literature behind it was generated almost entirely inside one indication, HIV-associated lipodystrophy, with visceral adipose tissue as the measured endpoint.

So the fork is the shape of the evidence, not the size of the effect. Semaglutide sits on the broadest human dataset this category has produced, spread across many populations and many years. Tesamorelin sits on a narrower one that is unusually precise about what it set out to measure.

The vials differ in a way that matters more than the sticker price. Reconstituted semaglutide holds for 28 days refrigerated. Tesamorelin's stated window is 24 hours. Two vials of the same nominal size are therefore not the same purchase, whatever the price-per-mg column says — read that figure together with the window, not instead of it.

Both arrive lyophilised, both are stored at 2–8 °C and protected from light, and both ship with the batch documentation described on the quality page. Neither is sold for human or veterinary use. Peptyds supplies both for laboratory research only.